Meet With...Pappas Capital
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
June 05, 2018 from 12:30 PM to 15:00 PM (PST)
$10 - $35
Since its founding in 1994, Pappas Capital has guided the launch and/or development of more than 70 life science companies, with a commitment to bringing promising products and technologies to market.
Scott Weiner and Kyle Rasbach, Partners at Pappas Capital, will be visiting JLABS @ South San Francisco on June 5, 2018 to provide an overview of Pappas Capital’s investment strategy and meet one-on-one with pre-selected companies.
Pappas Capital invests exclusively in the life sciences sector - biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures - across the United States and Canada. The firm has raised more than $500 million across multiple funds, and has built a team with extensive experience in sourcing, evaluating, building and exiting life science companies. More than one-third of their 70 portfolio companies have successfully been acquired or completed initial public offerings.
Kyle Rasbach | Partner, Pappas Capital read bio»
Scott Weiner | Partner, Pappas Capital read bio»
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:00 PM | One-on-One Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due May 10, 2018.
Presentation & Lunch
$25 | General Public
$35 | At the door
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on January 30th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must apply for a one-on-one meeting ahead of time. The one-on-one application period will close on May 10th,, 2018. Your application will be reviewed and you will be notified of acceptance by May 25th,, 2018. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Kyle Rasbach, Ph.D. | Partner, Pappas Capital
Kyle joined Pappas Capital in January 2018, bringing with him extensive experience in clinical pharmacology, basic science and healthcare equity research. Prior to joining Pappas, he was an equity research analyst and Vice President at T Rowe Price in Baltimore, where he managed pharmaceutical, specialty pharmaceutical and biotechnology investments for all T Rowe Price funds. During his time at T Rowe, Kyle led the firm's IPO investment in Pappas portfolio company CoLucid Pharmaceuticals (NASDAQ: CLCD), which was eventually sold to Eli Lilly for just under $1 billion. Prior to joining T Rowe, Kyle was an equity research associate and Vice President at Cowen and Company in Boston, where he covered global pharmaceutical equities. He completed his postdoctoral work in the laboratory of Bruce Spiegelman at Harvard Medical School, where he contributed to a number of high profile publications, including papers in Cell, Cell Metabolism, Nature and PNAS. Kyle received his Ph.D. and PharmD from the Medical University of South Carolina, and an MBA from the Citadel.
Scott Weiner | Partner, Pappas Capital
Scott joined Pappas Capital in 2006, bringing with him a wide network and broad transaction experience. Prior to Pappas Capital, Scott was an investment manager and research analyst at Silverback Asset Management’s life science fund where he focused on healthcare securities investing. Before joining Silverback, he spent three years at Chicago Growth Partners focusing on healthcare venture investments, and previous to that, he spent three and a half years in investment banking at Lehman Brothers where he worked in New York, London and Hong Kong.
Scott currently serves as a director for Milestone Pharmaceuticals and Reneo Pharmaceuticals, and as an observer for Envisia Therapeutics, IlluminOss Medical, Liquidia Technologies and Thrasos Therapeutics. He previously served as a director for Rotation Medical (acquired by Smith & Nephew), and as an observer for LipoScience (NASDAQ: LPDX; acquired by LabCorp) and TESARO (NASDAQ: TSRO). Scott is also a member of the Investor Advisory Board of the Florida Institute for the Commercialization of Public Research, and a board member for the Council for Entrepreneurial Development (CED). He received both a BS and MBA degree from Duke University.
About the Meet With... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.